This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CNCE Aktienübersicht
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Concert Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$8.37 |
| 52-Wochen-Hoch | US$8.55 |
| 52-Wochen-Tief | US$2.66 |
| Beta | 0.52 |
| 11 Monat Veränderung | 0% |
| 3 Monate Veränderung | 92.86% |
| 1 Jahr Veränderung | 203.26% |
| 33 Jahre Veränderung | -9.22% |
| 5 Jahre Veränderung | -64.31% |
| Veränderung seit IPO | -40.97% |
Aktuelle Nachrichten und Updates
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Aktionärsrenditen
| CNCE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.1% | -4.0% | 0.6% |
| 1Y | 203.3% | 18.1% | 32.1% |
Rendite im Vergleich zur Industrie: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
Rendite vs. Markt: CNCE exceeded the US Market which returned -5.5% over the past year.
Preisvolatilität
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: CNCE's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| CNCE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$520.71m |
| Gewinn(TTM) | -US$126.68m |
| Umsatz(TTM) | US$32.04m |
16.3x
Kurs-Umsatz-Verhältnis-4.1x
Kurs-Gewinn-VerhältnisIst CNCE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CNCE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$32.04m |
| Kosten der Einnahmen | US$102.70m |
| Bruttogewinn | -US$70.66m |
| Sonstige Ausgaben | US$56.02m |
| Umsatz | -US$126.68m |
Zuletzt gemeldete Gewinne
Sep 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.04 |
| Bruttomarge | -220.53% |
| Nettogewinnspanne | -395.36% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich CNCE auf lange Sicht entwickelt?
Historische Performance und Vergleiche